GLP-1 Comparison · Last verified: April 24, 2026
By The RX Index Editorial Team · FDA prescribing information for Foundayo and Zepbound verified · Pricing confirmed at LillyDirect, Ro, and Sesame Care · ATTAIN-1 and SURMOUNT-1 trial data cross-referenced against DailyMed
Foundayo vs Zepbound: Pill vs Shot,
Cost, and Which Works Better (2026)
Disclosure: The RX Index may earn a commission if you start an evaluation through our partner links. This does not change the medication price or the membership price you pay. This page is not medical advice — a licensed clinician must review your history before prescribing anything.
Bottom line up front
Zepbound produced more weight loss on average — about 20.9% of body weight at the 15 mg dose in 72-week trials, versus about 11.1% for Foundayo at the 17.2 mg dose.
Foundayo costs less at self-pay ($149–$349/month) than Zepbound ($299–$449/month on current offer pricing), and it's a once-daily pill — no needles, no refrigeration required. Both are made by Eli Lilly. Both are FDA-approved. Both work.
If your #1 goal is the biggest number on the scale and you're fine with a weekly shot, Zepbound wins. If you hate needles, travel often, or need the lower monthly spend, Foundayo wins. If your insurance covers one and not the other, that usually decides it.
~11.1%
Foundayo 17.2 mg · 72 wks · ATTAIN-1
~20.9%
Zepbound 15 mg · 72 wks · SURMOUNT-1
$149/mo
Foundayo starting self-pay (0.8 mg)
$299/mo
Zepbound starting self-pay (2.5 mg)
Ro carries both Foundayo and Zepbound, matches LillyDirect's self-pay pricing on the drug, and runs a free insurance coverage check. Clinician review required.
Check eligibility and pricing for Foundayo or Zepbound on Ro →Affiliate link — we may earn a commission at no cost to you.
Foundayo vs Zepbound at a glance
Foundayo (orforglipron) is a once-daily oral GLP-1 pill Eli Lilly launched after FDA approval on April 1, 2026. Zepbound (tirzepatide) is Eli Lilly's once-weekly GLP-1/GIP injection, FDA-approved since November 2023. They're made by the same company but are not the same drug — different molecules, different delivery, different average weight loss, and different price.
| Foundayo | Zepbound | |
|---|---|---|
| Best for | Oral pill, lower cash ramp, no needles | Strongest avg weight loss, weekly routine, or OSA indication |
| Active ingredient | Orforglipron (small-molecule, non-peptide) | Tirzepatide (dual GIP/GLP-1 peptide) |
| Maker | Eli Lilly | Eli Lilly |
| FDA approval | April 1, 2026 | November 8, 2023 |
| Indications | Chronic weight management | Chronic weight management + moderate-to-severe OSA in adults with obesity |
| Form | Oral tablet | Subcutaneous injection (single-dose vial, pen, or KwikPen) |
| Frequency | Once daily | Once weekly |
| Food restrictions | None — any time of day, with or without food | N/A — it's injected |
| Storage | Room temperature | Normally refrigerated; KwikPen: room temp up to 30 days |
| Starting self-pay | $149/month (0.8 mg) | $299/month (2.5 mg vial or KwikPen) |
| Maintenance self-pay | $299/mo (45-day refill rule at top 2 doses; $349/mo if window lapses) | $449/mo Self Pay Journey Program offer; $499–$699/mo regular pricing at top KwikPen doses if offer lapses |
| With savings card | As low as $25/month | As low as $25/month |
| Medicare Bridge (July 1, 2026) | ~$50/month | ~$50/month — KwikPen only (no single-dose pen or vial) |
| Top-dose weight loss, 72 wks | ~11.1% at 17.2 mg | ~20.9% at 15 mg |
| Boxed warning | Thyroid C-cell tumors | Thyroid C-cell tumors |
| Oral contraceptive warning | Backup method 30 days after start + each dose increase | Backup method 4 weeks after start + each dose escalation |
The honest admission, right up top
Zepbound produced more weight loss than Foundayo on average in separate label trials. We're not going to hide it to make Foundayo look like a better bet than it is. If the only thing you care about is the largest average drop on the scale and you can tolerate a weekly injection, see Zepbound eligibility and coverage on Ro — it's the stronger clinical choice on magnitude.
But Foundayo doesn't try to be the maximum-weight-loss pick. It's aimed at people who never started a GLP-1 because of needles, who quit because $449/month stopped being sustainable, who travel too much to manage refrigerated pens, or who already lost the weight and just want a simpler maintenance tool. 11% of a real body beats 21% of a hypothetical one every time.
Is Foundayo the pill version of Zepbound?
No. Foundayo is not "Zepbound in a pill." They share a manufacturer (Eli Lilly) and the GLP-1 receptor class, but the active ingredients, receptor targets, and results are different. Foundayo is orforglipron, a small-molecule non-peptide that activates the GLP-1 receptor only. Zepbound is tirzepatide, a peptide that activates two receptors — GLP-1 and GIP — and requires injection because peptides don't survive the stomach.
The confusion is common. Headlines say "Lilly's new weight-loss pill" and people assume it's the oral version of the shot they know. It isn't.
Foundayo (orforglipron)
A small-molecule drug — chemically stable enough to survive your stomach acid. No empty-stomach ritual required. Per the Foundayo label, geometric mean absolute bioavailability is about 77% after a 0.8 mg dose — exceptionally high for an oral GLP-1. Activates GLP-1 receptor only.
Zepbound (tirzepatide)
A peptide. Peptides break down in the gut, which is why tirzepatide has to be injected. Activates both GLP-1 and GIP receptors — the dual mechanism is the leading explanation for why Zepbound tends to produce larger average weight loss than single-target GLP-1s.
Can you take Foundayo and Zepbound together?
No. Both labels explicitly state that concomitant use with another GLP-1 receptor agonist is not recommended. Stacking them overlaps GLP-1 effects in ways that can increase GI side effects and hypoglycemia risk, especially if you're also on insulin or a sulfonylurea. If any online source suggests otherwise, ignore it.
Which works better for weight loss, Foundayo or Zepbound?
Zepbound produced more weight loss on average in separate 72-week trials. In adults with obesity and no type 2 diabetes, Zepbound 15 mg delivered an average weight loss of 20.9%, while Foundayo 17.2 mg delivered about 11.1%. These are parallel-trial results, not a head-to-head comparison, and no head-to-head trial between Foundayo and Zepbound has been published at their approved doses.
What the trial numbers actually show
| Trial | Drug & dose | Avg weight loss | ≥5% lost |
|---|---|---|---|
| ATTAIN-1 (72 wks, no T2D) | Foundayo 5.5 mg daily | ~7.4% | — |
| ATTAIN-1 (72 wks, no T2D) | Foundayo 9 mg daily | ~8.3% | — |
| ATTAIN-1 (72 wks, no T2D) | Foundayo 17.2 mg daily | ~11.1% | ~71.5% |
| SURMOUNT-1 (72 wks, no T2D) | Zepbound 5 mg weekly | 15.0% | 85% |
| SURMOUNT-1 (72 wks, no T2D) | Zepbound 10 mg weekly | 19.5% | 89% |
| SURMOUNT-1 (72 wks, no T2D) | Zepbound 15 mg weekly | 20.9% | 91% |
Source: FDA prescribing information for Foundayo and Zepbound (DailyMed), plus Eli Lilly's clinical trial readouts. Roughly 30–57% of Zepbound SURMOUNT-1 participants lost at least 20% of body weight — territory similar to some bariatric procedures.
What that means for an actual person (250 lbs starting weight)
| Drug (top dose) | Trial avg % loss | Lbs lost (250-lb person) |
|---|---|---|
| Foundayo 17.2 mg | ~11.1% | ~27.8 lbs |
| Zepbound 15 mg | ~20.9% | ~52.3 lbs |
| Gap at 72 weeks | ~24.5 lbs | |
That's a real difference. Not a marketing one. For someone with 100+ pounds to lose, Zepbound is closer to what they actually need. For someone 20–30 lbs from goal, either gets them there.
Why Zepbound pulls ahead: the GIP theory
Tirzepatide activates two hormone receptors (GLP-1 + GIP); orforglipron activates one (GLP-1). GIP activation appears to add meaningful metabolic punch: more appetite suppression, better insulin sensitivity, more efficient fat loss. Every Zepbound-vs-single-target-GLP-1 comparison has pointed the same direction — Zepbound wins on magnitude.
The honest caveat
No head-to-head trial between Foundayo and Zepbound has been published at their approved doses. Cross-trial comparisons have real limits — different populations, different comparators, different protocols. The ~11% vs ~21% gap is the best estimate available, not a personal prediction. Your own response could land anywhere in the distribution.
How much does Foundayo cost vs Zepbound in 2026?
Foundayo is cheaper at self-pay. Starting dose is $149/month. Maintenance tops out at $299–$349/month. Zepbound starts at $299/month self-pay and climbs to $449/month for maintenance doses under the Self Pay Journey Program offer — regular pricing is $499 or $699/month at higher KwikPen doses if the offer lapses. With a commercial insurance savings card, either can drop to as low as $25/month.
The 6-month cash ramp — side by side
People don't pay the same price every month for their first 6 months — they're titrating through doses. Here's the standard ramp at LillyDirect and matched Ro cash pricing:
| Month | Foundayo dose | Foundayo cash | Zepbound dose | Zepbound cash |
|---|---|---|---|---|
| 1 | 0.8 mg daily | $149 | 2.5 mg weekly | $299 |
| 2 | 2.5 mg daily | $199 | 5 mg weekly | $399 |
| 3 | 5.5 mg daily | $299 | 7.5 mg weekly | $449 |
| 4 | 9 mg daily | $299 | 10 mg weekly | $449 |
| 5 | 14.5 mg daily | $299* | 12.5 mg weekly | $449 |
| 6 | 17.2 mg daily | $299* | 15 mg weekly | $449 |
| 6-month total | $1,544 | $2,494 | ||
*Foundayo 14.5 mg and 17.2 mg are $299/month only if you refill within 45 days. Miss the window: $349/month. The 45-day refill rule also applies to Zepbound KwikPen pricing — lapse past 45 days and regular pricing applies: $499/month (7.5 mg KwikPen) or $699/month (10/12.5/15 mg KwikPen).
Over the first 6 months, Foundayo costs about $950 less than Zepbound at self-pay. Over 12 months, the gap grows to roughly $1,800.
72-week cost-per-pound comparison
The trial comparison is measured at 72 weeks — that's about 17 Foundayo refills or 18 Zepbound KwikPen refills. At top-dose offer pricing, 72 weeks costs roughly:
| Scenario | Foundayo | Zepbound |
|---|---|---|
| 72-week medication cost (self-pay) | ~$4,800–$5,100 | ~$7,900 |
| Lbs lost (250-lb person, trial avg) | ~27.8 lbs | ~52.3 lbs |
| Cost per pound lost (self-pay) | ~$180/lb | ~$150/lb |
| 72-week cost (insured, $25/mo) | ~$425 | ~$450 |
| Cost per pound lost (insured) | ~$15/lb | ~$9/lb |
Zepbound is more dollar-efficient per pound even though it's more expensive per month. Foundayo wins on absolute spend if total budget is the binding constraint. When insurance covers both at $25/month, Zepbound becomes meaningfully cheaper per pound lost — the one exception where Zepbound is cheaper in both senses.
See your actual cost per pound lost
Sticker price tells you the monthly sting. Cost per pound lost tells you what you're actually buying. Enter your starting weight and pricing channel below.
Your personalized cost-per-pound estimate
Foundayo
~27.8 lbs
avg lost at 17.2 mg, 72 wks
~$183/lb
Total ~$5,083 over 72 wks
Zepbound
~52.3 lbs
avg lost at 15 mg, 72 wks
~$146/lb
Total ~$7,633 over 72 wks
Your numbers:
Self-pay: Foundayo's 72-week total is ~$5,083 vs Zepbound's ~$7,633 — roughly $2,550 more. On a per-pound basis, Zepbound costs ~$146/lb vs Foundayo's ~$183/lb. Zepbound is more dollar-efficient per pound even though it costs more per month. If total budget is the binding constraint, Foundayo wins.
Based on FDA label trial averages — not a personal prediction. Your actual response could land anywhere in the distribution. Calculator uses 17 months (≈72 weeks) at top-dose maintenance pricing.
Does insurance or Medicare cover Foundayo or Zepbound?
It depends on your plan. Commercial insurance often covers one or both with prior authorization — savings cards can bring eligible patients to as low as $25/month for either drug. Medicare Part D beneficiaries can access Foundayo or Zepbound KwikPen at about $50/month through the CMS Medicare GLP-1 Bridge, running July 1, 2026 through December 31, 2027. Medicaid, Tricare, and VA coverage varies.
Commercial insurance (most common path)
- Prior authorization required: BMI ≥30 (or ≥27 with a weight-related condition), comorbidities, prior lifestyle attempts
- Zepbound has been on formularies since 2023 — more established coverage
- Foundayo was approved April 1, 2026 — plans still adding it, coverage less settled
- If covered, savings cards bring both to as low as $25/month for commercial patients
- Government-insured patients (Medicare, Medicaid, Tricare, VA) cannot use savings cards
Medicare GLP-1 Bridge (July 1 – December 31, 2027)
- Covers Foundayo and Zepbound KwikPen at ~$50/month
- Does not include Zepbound single-dose pen or single-dose vial
- Applies to eligible Medicare Part D beneficiaries meeting CMS BMI and comorbidity criteria
- Prior authorization required via single central processor — not your individual Part D plan
- This is the single biggest factor in the Foundayo vs Zepbound decision if you're on Medicare
Don't guess at your copay — check first
Ro's free GLP-1 Insurance Coverage Checker contacts your insurance company and tells you what your specific plan covers in under a minute — including prior authorization requirements and estimated copay. Their insurance concierge handles the PA paperwork for commercial plans. No commitment.
Check your plan's coverage on Ro →Are the side effects different?
The side-effect profiles overlap a lot because both drugs activate the GLP-1 receptor. Both commonly cause GI effects during titration — nausea, constipation, diarrhea, vomiting. Both carry a boxed warning for thyroid C-cell tumors. The main difference: Zepbound causes injection-site reactions, and headache is listed as a common adverse reaction on the Foundayo label but not on Zepbound's common-reactions table.
| Side effect | Foundayo | Zepbound |
|---|---|---|
| Nausea | ✓ Common | ✓ Common |
| Constipation | ✓ Common | ✓ Common |
| Diarrhea | ✓ Common | ✓ Common |
| Vomiting | ✓ Common | ✓ Common |
| Abdominal pain / indigestion | ✓ Common | ✓ Common |
| Gas / burping / GERD | ✓ Common | ✓ Common |
| Headache | ✓ Listed as common (≥5%) | Appears only as low-blood-sugar symptom |
| Fatigue | ✓ Listed | Not in common-reactions table |
| Hair loss | ✓ Listed | Not in common-reactions table |
| Abdominal distension / bloating | ✓ Listed | Not in common-reactions table |
| Injection-site reactions | — | ✓ Common (redness, bruising, lumps) |
| Weekly nausea rhythm (day after shot) | — | ✓ Some users |
| Thyroid C-cell tumor boxed warning | ✓ | ✓ |
| Oral contraceptive interaction | ✓ 30-day backup after start + each dose ↑ | ✓ 4-week backup after start + each dose ↑ |
Serious warnings — shared by both drugs
Both are contraindicated for personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or prior serious hypersensitivity reaction to the drug.
Both label warnings include: pancreatitis, severe GI reactions, acute kidney injury from dehydration, hypoglycemia risk with insulin/sulfonylureas, gallbladder disease, pulmonary aspiration during anesthesia, diabetic retinopathy complications in T2D, severe gastroparesis ("not recommended"). Tell your surgeon and anesthesiologist before any procedure.
Nuance: the Foundayo label notes orforglipron was non-carcinogenic in 2-year rat/mouse studies — a meaningful distinction from the standard GLP-1 class warning on Zepbound.
Can you switch from Zepbound to Foundayo?
Yes — under a prescriber's supervision. Switching between GLP-1s happens in real-world practice. You never take them at the same time. And before you switch, know the relevant number from Lilly's ATTAIN-MAINTAIN trial:
ATTAIN-MAINTAIN switching data
Patients who had lost weight on Zepbound and switched to orforglipron maintained their weight loss with an average difference of about 5 kg (~11 lbs) at 52 weeks. Patients who switched from Wegovy had an average difference of about 0.9 kg (~2 lbs).
Critical caveat: ATTAIN-MAINTAIN used investigational 24 mg or 36 mg orforglipron doses — higher than the approved Foundayo maximum of 17.2 mg. Treat this as a directional maintenance signal, not a guaranteed outcome at approved doses. Source: Lilly ATTAIN-MAINTAIN topline results (December 18, 2025).
| Reason to consider switching | Realistic expectation |
|---|---|
| Cost ($449/month self-pay gets heavy) | May maintain most weight lost, with some give-back (~5 kg directional signal at investigational doses) |
| Injection fatigue | Foundayo is a daily pill — no shots, no injection-site reactions |
| Travel friction (refrigerated pens) | Foundayo is room-temperature, no refrigeration needed |
| Reached goal weight, want simpler maintenance | Reasonable conversation, with realistic expectations about maintenance trade-off |
| Insurance now covers Foundayo but not Zepbound | If coverage works, the formulary usually decides |
One rule that's absolute
Do not combine Foundayo with Zepbound or any other GLP-1 receptor agonist. Both labels say concomitant use is not recommended. There is no combined-use protocol to ask about.
Ro carries Foundayo, Zepbound pen, and Zepbound KwikPen. You can have the conversation with a clinician without also changing providers.
Who should choose Foundayo?
Foundayo is the right medication to discuss with your clinician if you want an FDA-approved oral GLP-1, strongly prefer avoiding injections, need the lower self-pay starting price, travel often enough that refrigerated pens are a real problem, or you're exploring a simpler maintenance option after an injectable. It's not the right pick if maximum average weight loss is your top priority.
Foundayo is a clean fit if you're saying…
- "I hate needles and that's not going to change."
- "The injection is literally why I haven't started."
- "I travel a lot and refrigerated pens are a headache."
- "I'm paying cash and I need the cheapest reasonable option." ($149 starter)
- "My insurance covers Foundayo but not Zepbound."
- "I've hit my goal on Zepbound and want simpler maintenance."
- "I want an FDA-approved brand-name — not a compounded version."
- "I need a pill that doesn't require fasting or timed water."
Foundayo probably isn't your fit if…
- Your only goal is the largest number on the scale
- You have obesity with moderate-to-severe obstructive sleep apnea (Zepbound has the OSA indication; Foundayo doesn't)
- You'll struggle to remember a daily pill (a weekly shot is more forgiving)
Ro matches LillyDirect's Foundayo cash pricing. Free insurance coverage check included.
Who should choose Zepbound?
Zepbound is the right medication to discuss with your clinician if you want the strongest average weight-loss results, prefer a once-weekly routine, have obesity with moderate-to-severe obstructive sleep apnea (the only GLP-1 with an on-label OSA indication), have commercial insurance that covers it at a low copay, or have significant weight-related comorbidities where efficacy matters more than convenience.
Zepbound is a clean fit if you're saying…
- "I want the best average result an FDA-approved medication can deliver right now."
- "One shot a week fits my life better than one pill a day."
- "I have obesity and moderate-to-severe obstructive sleep apnea."
- "My doctor says weight is a primary driver of my cardiovascular risk."
- "My insurance covers Zepbound at $25/month."
- "I want access to the KwikPen."
Zepbound probably isn't your fit if…
- The injection is what's keeping you from starting
- Cash price is the single binding constraint and insurance won't help
- You have severe gastroparesis
- A modest weight-loss goal is all you need
Ro lists Zepbound KwikPen at matched LillyDirect pricing. Insurance concierge handles prior authorization.
Who should skip both Foundayo and Zepbound (for now)?
We'd rather lose you as a potential reader than push a medication toward someone it's wrong for.
Hard no (both drugs)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to the drug or any ingredient
- Current pregnancy — both labels say to discontinue when pregnancy is recognized; Foundayo advises effective contraception during treatment
Not recommended per label
- Severe gastroparesis
Clinician must weigh the decision
- History of pancreatitis or gallbladder disease
- Significant kidney disease (especially with vomiting/diarrhea causing dehydration)
- On insulin or a sulfonylurea (hypoglycemia risk — dose adjustments needed)
- Upcoming surgery under general anesthesia (tell your surgical team — GLP-1s slow gastric emptying)
- Breastfeeding (Foundayo not recommended for nursing women; Zepbound data limited)
- BMI below 27 with no weight-related condition — outside FDA-approved population for either drug
The RX Index Decision Matrix
Most comparison pages give you a verdict with no methodology. Here's ours. We score against six weighted criteria: expected weight-loss strength (30%), cost and access (25%), adherence and friction (20%), safety complexity (10%), insurance and Medicare path (10%), and switching/maintenance fit (5%).
The scoring framework
| Category | Weight | What it captures |
|---|---|---|
| Expected weight-loss strength | 30% | The core reason people take a GLP-1 |
| Cost & access | 25% | Sticker price, insurance path, real out-of-pocket |
| Adherence & friction | 20% | Pill vs shot, daily vs weekly, travel, storage |
| Safety complexity | 10% | Contraindications, interactions, clinician-review flags |
| Insurance / Medicare / provider path | 10% | Real-world access in 2026 |
| Switching / maintenance fit | 5% | Current GLP-1 users considering a change |
Use-case scoring
| Use case | Foundayo | Zepbound | Winner |
|---|---|---|---|
| Maximum average weight loss | 6/10 | 10/10 | Zepbound |
| Lowest listed cash starting price | 9/10 | 6/10 | Foundayo |
| Avoiding injections | 10/10 | 3/10 | Foundayo |
| Weekly routine simplicity | 6/10 | 9/10 | Zepbound |
| Obesity + OSA indication | 4/10 | 10/10 | Zepbound |
| Maintenance after injectable success | 7/10 | 8/10 | Depends on give-back tolerance |
| Commercial insurance with savings card | 8/10 | 8/10 | Tie — both ~$25/mo |
| Medicare Bridge (July 2026+) | 8/10 | 7/10 | Slight Foundayo edge — Zepbound KwikPen only |
| Traveling often / no refrigeration needed | 10/10 | 4/10 | Foundayo |
| Severe obesity with comorbidities | 6/10 | 10/10 | Zepbound |
| No head-to-head trial caveat | — | — | Comparison is directional, not predictive |
Zepbound verdict
Default winner when maximum average weight loss matters most and the patient can start, afford, and stay on a weekly injection — especially for significant weight to lose, weight-driven comorbidities, or OSA.
Foundayo verdict
Winner when the real-world barrier is the injection itself, the cash-price ramp, travel logistics, simpler maintenance after injectable success, or when insurance covers Foundayo and not Zepbound.
Where can you get Foundayo or Zepbound online?
This is a money page and we're not going to pretend otherwise. But we're also not going to recommend a provider that doesn't legitimately carry the medications this page is about.
Option 1 — Ro (primary recommendation)
- Carries: Foundayo, Zepbound KwikPen (cash-pay), Zepbound pen (insurance pathways), Wegovy pill and pen
- Medication pricing: matches LillyDirect — no markup on the medication itself
- Ro Body membership: $39 for first month, then as low as $74/month with annual plan paid upfront ($149/month month-to-month)
- Insurance support: concierge handles prior authorization on commercial plans; free GLP-1 Insurance Coverage Checker
- Why Ro wins for this comparison: Ro carries both drugs — your medication choice doesn't lock in a provider choice. Switch between Foundayo and Zepbound without changing clinicians
$39 first month · as low as $74/mo annual · medication priced at LillyDirect match
Option 2 — Sesame Care (secondary alternative)
Also offers Foundayo and Zepbound alongside Wegovy, Ozempic, Mounjaro, and Saxenda. Provider-choice model — you pick a clinician from a marketplace. Good alternative if choosing your own clinician matters to you. Compare pricing against Ro before assuming either is cheaper.
See Foundayo and Zepbound on Sesame Care →Option 3 — LillyDirect (manufacturer-direct)
Lilly's own pharmacy. Medication pricing is the same as Ro. Difference: LillyDirect doesn't provide a clinician — you need an existing prescription. Fine if you already have a prescription and don't want telehealth. If you want one platform to handle prescription + insurance + pharmacy + follow-up, Ro or Sesame is simpler.
What we did not recommend — and why
We didn't recommend any compounded GLP-1 provider on this page. Compounded GLP-1s are a different product with a different regulatory status. Mixing them into an FDA-approved-brand comparison blurs what you're actually deciding between.
What real people are saying about this decision
We use Reddit and forum language to understand the questions real people are asking — not as medical evidence.
"I'm planning to switch to the pill this week. I'm hopeful it will work because shot anxiety was getting to be too much."
— r/Zepbound, January 2026
"I can't seem to find much data on whether someone who is at or near goal might maintain on Foundayo."
— r/Zepbound, January 2026
"The pricing is so much cheaper for pills."
— r/Zepbound, December 2025
What we actually verified (last checked April 24, 2026)
| What we checked | Primary source | What we confirmed |
|---|---|---|
| Foundayo FDA approval and indication | FDA.gov press release (4/1/2026), Eli Lilly announcement | April 1, 2026; chronic weight management |
| Foundayo dosing, boxed warning, safety | Foundayo prescribing information on DailyMed | 0.8→17.2 mg daily; thyroid C-cell tumor boxed warning; oral contraceptive warning |
| Foundayo self-pay pricing | LillyDirect Foundayo page + Lilly 4/1/2026 press release | $149, $199, $299, $299, $299/$349, $299/$349 by dose; 45-day refill rule at top two doses |
| Foundayo ATTAIN-1 trial results | Foundayo prescribing information on DailyMed | 11.1% mean weight loss at 17.2 mg, 72 weeks, no diabetes; 71.5% ≥5% at top dose |
| Zepbound FDA indications | Zepbound prescribing information on DailyMed | Chronic weight management + moderate-to-severe OSA in adults with obesity |
| Zepbound dosing and safety | Zepbound prescribing information on DailyMed | 2.5→15 mg weekly; thyroid C-cell tumor boxed warning; oral contraceptive warning (4-week backup) |
| Zepbound self-pay pricing | zepbound.lilly.com/savings + Lilly 12/1/2025 press release | $299/2.5 mg, $399/5 mg, $449/7.5–15 mg Self Pay Journey; $499/$699 regular KwikPen if offer lapses |
| Zepbound SURMOUNT-1 trial results | Zepbound prescribing information on DailyMed | 20.9% mean weight loss at 15 mg, 72 weeks, no diabetes |
| Savings card terms | zepbound.lilly.com/savings + Foundayo savings page | As low as $25/month for commercially insured patients; government beneficiaries excluded |
| Medicare GLP-1 Bridge | CMS Medicare GLP-1 Bridge program page | July 1, 2026 – Dec 31, 2027; ~$50/month; includes Foundayo and Zepbound KwikPen only |
| ATTAIN-MAINTAIN switching data | Lilly ATTAIN-MAINTAIN topline release (Dec 18, 2025) | ~0.9 kg gap for Wegovy switchers, ~5 kg for Zepbound switchers — on investigational 24/36 mg orforglipron |
| Ro Foundayo + Zepbound access | ro.co/weight-loss/ | Ro lists Foundayo and Zepbound KwikPen at matched cash-pay pricing; Zepbound pen through insurance |
| Ro Body membership pricing | ro.co/weight-loss/pricing | $39 first month; $149/month ongoing; as low as $74/month with annual prepay |
What we did not verify
- Insurance formulary coverage for individual plans (too variable — use Ro's coverage checker)
- Retail pharmacy cash pricing beyond LillyDirect (varies; LillyDirect is typically cheapest)
- Sesame Care's real-time Foundayo and Zepbound pricing by individual clinician
- State-by-state Ro availability
If you find a fact on this page that's out of date, email us. We review pricing monthly and re-verify the full page quarterly.
Foundayo vs Zepbound FAQ
Is Foundayo the same as Zepbound?
No. Both are Eli Lilly products, but Foundayo contains orforglipron — a small-molecule non-peptide oral GLP-1 receptor agonist — while Zepbound contains tirzepatide, a peptide that activates both GLP-1 and GIP receptors via weekly subcutaneous injection. Different drugs, different mechanisms, different results.
Is Foundayo as effective as Zepbound for weight loss?
Not on average. At their respective top doses in separate 72-week trials in adults without type 2 diabetes, Zepbound 15 mg produced ~20.9% mean weight loss and Foundayo 17.2 mg produced ~11.1%. No head-to-head trial at approved doses has been published — the comparison is across parallel trials, not a direct one.
Is Foundayo cheaper than Zepbound?
At self-pay list prices, yes. Foundayo runs $149 to $349 per month depending on dose and refill timing; Zepbound runs $299 to $449 under current offer pricing, with regular KwikPen pricing as high as $499–$699 at top doses if the 45-day refill window lapses. With a commercial insurance savings card, both can be as low as $25/month. Medicare GLP-1 Bridge pricing (from July 1, 2026) is approximately $50/month for either Foundayo or Zepbound KwikPen.
Can you take Foundayo and Zepbound together?
No. Both FDA prescribing labels say concomitant use with another GLP-1 receptor agonist is not recommended. Combining them does not double the weight loss — it overlaps the same GLP-1 effects and can increase GI side effects and hypoglycemia risk if you're also on insulin or a sulfonylurea.
Can I switch from Zepbound to Foundayo?
Yes, under a prescriber's supervision — but know the context. Lilly's ATTAIN-MAINTAIN trial found that patients who had lost weight on Zepbound and switched to orforglipron maintained their weight loss with an average difference of about 5 kg (~11 lbs) at 52 weeks, versus about 0.9 kg (~2 lbs) for Wegovy switchers. That study used investigational 24 mg or 36 mg doses, not the approved 17.2 mg Foundayo max, so treat it as a directional maintenance signal. Your clinician decides the switch timing and titration.
Is Foundayo a pill or an injection?
Foundayo is a pill — the first non-peptide small-molecule oral GLP-1 receptor agonist approved by the FDA. Unlike the Wegovy pill, it can be taken at any time of day with or without food or water.
Does insurance cover Foundayo like it covers Zepbound?
Coverage varies. Zepbound has been on commercial formularies since 2023, so more plans cover it. Foundayo was approved April 1, 2026 and plans are still adding it. Use Ro's free GLP-1 Insurance Coverage Checker to see what your specific plan covers.
What are the main side effects of Foundayo and Zepbound?
Both commonly cause nausea, constipation, diarrhea, and vomiting, mostly during dose escalation. Both carry a boxed warning for thyroid C-cell tumors. Both warn that oral birth control pills may be less effective due to delayed gastric emptying — backup contraception is recommended for 30 days (Foundayo) or 4 weeks (Zepbound) after starting and each dose increase. Zepbound also causes injection-site reactions. Headache is listed as common on the Foundayo label but not in Zepbound's common-reactions table.
Is Foundayo approved for obstructive sleep apnea like Zepbound?
No. As of April 24, 2026, Zepbound is the only FDA-approved GLP-1 medication with an indication for moderate-to-severe obstructive sleep apnea in adults with obesity. Foundayo is approved for chronic weight management only.
Does Medicare cover Foundayo or Zepbound?
Starting July 1, 2026, the CMS Medicare GLP-1 Bridge covers eligible Medicare Part D beneficiaries for Foundayo and Zepbound KwikPen at approximately $50/month. The program runs through December 31, 2027. It does not include Zepbound single-dose pen or single-dose vial. Prior authorization and a prescription are required.
Does Foundayo require fasting like the Wegovy pill?
No. Foundayo can be taken at any time of day, with or without food or water. That's its biggest practical advantage over the Wegovy pill, which requires an empty stomach, only 4 oz of water, and a 30-minute fasting wait before eating or drinking.
Still deciding?
Foundayo and Zepbound are both legitimate, FDA-approved, Eli Lilly GLP-1 medications. They solve the same problem two different ways. Zepbound wins on magnitude. Foundayo wins on ease and price. Your insurance, your goals, your needle tolerance, and your budget decide the rest.
If you want one flexible path that keeps your options open, Ro carries both, matches LillyDirect's pricing, and their insurance concierge handles prior authorization for commercial plans.
Affiliate link — $39 first month of Ro Body, then as low as $74/month with annual plan paid upfront. Medication priced at LillyDirect match. Free GLP-1 Insurance Coverage Checker. Clinician review required before anything is prescribed.
Related reading
Last verified: April 24, 2026 by The RX Index Editorial Team. Researched and written using primary sources from the FDA, DailyMed (Foundayo and Zepbound prescribing information), Eli Lilly, LillyDirect, Ro, and CMS. Pricing reviewed monthly; full page re-verified quarterly. Next scheduled review: May 24, 2026.
Disclosure: The RX Index earns referral fees from Ro and Sesame Care through the affiliate links on this page. We do not earn fees from Eli Lilly, LillyDirect, Novo Nordisk, or NovoCare. Recommendations reflect our editorial judgment — affiliate economics decide only which legitimate provider we feature when two providers are genuinely tied on fit. This is not medical advice.